Lupus (SLE) trials in China

In China 163 Also abroad 354

163 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
Where
Hangzhou, Hefei
Age
18 years and over
People
12
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT06892145
No phaseNot yet taking people in China
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Where
Tianjin
Age
18 years to 65 years
People
24
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07212322
Phase 1/2Taking people
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Where
Shanghai
Age
18 years to 65 years
People
40
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06182969
Early phase 1Taking people
Allogeneic UCB-derived CAR-T for SLE
Where
Chengdu, Yancheng
Age
18 years to 75 years
People
48
Run by
Chengdu Ucello Biotechnology Co., Ltd.
See details and how to joinNCT07274059
Early phase 1Not yet taking people in China
CD19/BCMA CAR-T for SLE
Where
Chengdu
Age
18 years to 75 years
People
24
Run by
Chengdu Ucello Biotechnology Co., Ltd.
See details and how to joinNCT07266337
Phase 2Taking people
A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
Where
Nanjing
Age
18 years to 70 years
People
51
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07229742
Phase 1Taking people
Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
Where
Hangzhou
Age
5 years and over
People
6
Run by
Mao Jianhua
See details and how to joinNCT06789107
Phase 1/2Taking people
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
Where
Beijing
Age
18 years to 70 years
People
198
Run by
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
See details and how to joinNCT07185269
Phase 1Taking people
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
Where
Wuhan
Age
18 years to 60 years
People
12
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07031713
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
Where
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Wuhan, Xiamen, Xi’an, Yangzhou
Age
18 years to 75 years
People
24
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07038382
Phase 1Taking people
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
Where
Hangzhou
Age
5 years and over
People
18
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07233642
Phase 1Taking people
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Where
Tianjin
Age
18 years and over
People
12
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06941129
Phase 1Taking people
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
Where
Taiyuan, Wuhan
Age
18 years to 60 years
People
25
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06400537
Early phase 1Taking people
Safety Study of CC312 in Autoimmune Disease Patients
Where
Tianjin
Age
18 years and over
People
18
Run by
CytoCares Inc
See details and how to joinNCT06888960
Phase 1Taking people
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
Where
Chengdu
Age
18 years to 65 years
People
32
Run by
CytoCares Inc
See details and how to joinNCT07177911
Early phase 1Taking people
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 70 years
People
20
Run by
Shanghai Cell Therapy Group Co.,Ltd
See details and how to joinNCT07174843
No phaseTaking people
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
Where
Hefei
Age
18 years and over
People
18
Run by
Anhui Provincial Hospital
See details and how to joinNCT07121777
Phase 1Taking people
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
Where
Beijing
Age
18 years to 70 years
People
12
Run by
Juventas Cell Therapy Ltd.
See details and how to joinNCT06826430
Phase 1Taking people
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Where
Shanghai
Age
18 years to 70 years
People
30
Run by
RenJi Hospital
See details and how to joinNCT06249438
No phaseNot yet taking people in China
A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus
Where
Wuhan
Age
18 years to 65 years
People
24
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06900764
Phase 1Taking people
Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
Where
Beijing
Age
18 years to 65 years
People
20
Run by
Chinese SLE Treatment And Research Group
See details and how to joinNCT06881290
No phaseTaking people
CAR-T Cells Therapy for Patients With Autoimmune Diseases
Where
Hefei
Age
18 years and over
People
18
Run by
Anhui Provincial Hospital
See details and how to joinNCT07052565
Phase 1/2Taking people
Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells
Where
Shenzhen
Age
18 years to 65 years
People
58
Run by
Shenzhen Beike Bio-Technology Co., Ltd.
See details and how to joinNCT07041801
Phase 1/2Not yet taking people in China
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
Where
Shanghai
Age
18 years to 65 years
People
12
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07000292
No phaseTaking people
Long-Term Outcomes in SLE at Peking University People's Hospital
Where
Beijing
Age
18 years and over
People
1,000
Run by
Peking University People's Hospital
See details and how to joinNCT07005479